OPKO Health (NASDAQ:OPK) Sets New 12-Month Low After Analyst Downgrade

OPKO Health, Inc. (NASDAQ:OPK)’s share price reached a new 52-week low during mid-day trading on Wednesday after Barrington Research downgraded the stock from an outperform rating to a market perform rating. The stock traded as low as $1.0950 and last traded at $1.0650, with a volume of 999750 shares traded. The stock had previously closed at $1.21.

Several other research firms have also recently issued reports on OPK. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Tuesday, April 21st. Wall Street Zen cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $1.55.

OPKO Health News Summary

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO gained a 15% equity stake in Nicoya via an amended EirGen agreement and reinforced Nicoya’s commitment to commercialize RAYALDEE® in Greater China; RAYALDEE is already approved in Macau and the parties expect regulatory approvals in China/related territories in 2027 — this raises potential near- to medium-term royalty/sales upside and equity value. OPKO Health Expands Nicoya Agreement
• Positive Sentiment: BioReference (an OPKO company) launched BioReference Direct™, a direct-to-consumer digital testing platform that could broaden access, diversify revenue channels, and help stabilize diagnostics volumes via online ordering and expanded patient reach. BioReference Launches BioReference Direct
• Positive Sentiment: OPKO reported Q1 EPS roughly in line with estimates and noted growth in pharma product sales, which helped earnings despite top-line pressure — a sign the company’s commercial pharma mix is contributing to margins. OPKO Health Q1 Earnings In-Line
• Neutral Sentiment: HC Wainwright published quarterly and FY2027 EPS estimates (quarterly at -$0.07, FY2027 at -$0.30), largely reaffirming quarterly losses and indicating modestly more conservative full-year expectations versus consensus — useful modeling data but not a material surprise.
• Negative Sentiment: Revenue fell ~25.7% year-over-year in Q1 and quarterly revenue missed consensus (reported ~$124.2M vs. est. ~$130.5M), driven by a smaller BioReference diagnostics base — a near-term drag on top-line growth and valuation. OPKO Health Q1 Earnings In-Line
• Negative Sentiment: Barrington Research downgraded OPKO from “outperform” to “market perform,” which may reduce buy-side enthusiasm and limit near-term upside from some institutional investors. Barrington Downgrade

Institutional Investors Weigh In On OPKO Health

A number of institutional investors have recently made changes to their positions in OPK. Caprock Group LLC acquired a new stake in shares of OPKO Health during the third quarter valued at about $26,000. Zacks Investment Management acquired a new stake in shares of OPKO Health during the fourth quarter valued at about $27,000. StoneX Group Inc. acquired a new stake in shares of OPKO Health during the fourth quarter valued at about $27,000. Swiss Life Asset Management Ltd acquired a new stake in shares of OPKO Health during the third quarter valued at about $30,000. Finally, Savant Capital LLC acquired a new stake in shares of OPKO Health during the third quarter valued at about $33,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Trading Up 1.4%

The firm has a market capitalization of $849.48 million, a price-to-earnings ratio of -4.17 and a beta of 1.49. The business’s 50-day simple moving average is $1.18 and its two-hundred day simple moving average is $1.28. The company has a quick ratio of 3.52, a current ratio of 3.61 and a debt-to-equity ratio of 0.28.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.07). OPKO Health had a negative net margin of 36.63% and a negative return on equity of 16.78%. The business had revenue of $124.20 million during the quarter, compared to analysts’ expectations of $130.51 million. During the same period last year, the business earned ($0.10) earnings per share. The business’s revenue for the quarter was down 17.1% on a year-over-year basis. Equities analysts forecast that OPKO Health, Inc. will post -0.27 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.